STOCK TITAN
  1. Home
  2. News
  3. SNY

Sanofi American Depositary Shares (Each representing one-half of one ordinary share) - SNY STOCK NEWS

Welcome to our dedicated page for Sanofi American Depositary Shares (Each representing one-half of one ordinary share) news (Ticker: SNY), a resource for investors and traders seeking the latest updates and insights on Sanofi American Depositary Shares (Each representing one-half of one ordinary share) stock.

Sanofi American Depositary Shares (symbol: SNY) represent a large global healthcare company headquartered in Paris, France, established in 1973. Sanofi specializes in the development and marketing of pharmaceuticals, specifically focusing on oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments, and vaccines. One of its most significant achievements includes the successful launch of Dupixent, a drug that accounts for over 20% of the company's total sales, although profits are shared with Regeneron.

Sanofi's Global Presence
Approximately 40% of Sanofi's revenue comes from the United States, 25% from Europe, and the remaining largely from emerging markets. This diversified revenue stream underscores Sanofi's global reach and adaptability in various healthcare markets.

Recent Developments
Sanofi has been active in strategic mergers and acquisitions to enhance its product portfolio. For instance, in January 2024, Sanofi announced the acquisition of Inhibrx's assets related to INBRX-101, a therapy for alpha-1 antitrypsin deficiency. This acquisition is valued at approximately $2.2 billion and aims to expand Sanofi's capabilities in rare diseases.

Partnerships and Innovations
Sanofi has also entered into a co-exclusive licensing agreement with Novavax to co-commercialize Novavax's adjuvanted COVID-19 vaccine globally, excluding certain regions where Novavax already has agreements. This partnership is expected to enhance Novavax's COVID-19 vaccine reach and combine it with Sanofi's flu vaccines for a more comprehensive approach to respiratory diseases.

Sustainability and Social Responsibility
Sanofi is committed to sustainability and social responsibility, aiming to improve healthcare access and outcomes worldwide. The company emphasizes eco-friendly practices and actively pursues projects that align with these values.

Financial Outlook
Sanofi continues to invest in research and development to drive future growth and innovation. The company's robust financial health allows it to navigate market challenges and capitalize on new opportunities in the pharmaceutical sector.

News

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
News

Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases

Rhea-AI Summary
Synthekine Inc. announced a collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases. Synthekine will receive a $40 million upfront payment and is eligible for additional milestones and royalties on net sales. The collaboration aims to develop selective agonists that expand therapeutic index, focusing on advancing Synthekine’s multiple approaches to optimizing IL-10. Sanofi will assume sole responsibility for subsequent preclinical, clinical, and commercial activities for the IL-10 therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Rhea-AI Summary
Inhibrx, Inc. (Nasdaq: INBX) and Sanofi (Nasdaq: SNY) have entered into a definitive agreement under which Sanofi will acquire all assets and liabilities associated with INBRX-101. Inhibrx shareholders will receive $30 per share in cash, a CVR of $5, and 0.25 shares in New Inhibrx. Sanofi will pay off Inhibrx's outstanding debt and capitalize New Inhibrx with $200 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
News

Scribe Therapeutics Expands In Vivo Collaboration with Sanofi to Second Target

Rhea-AI Summary
Scribe Therapeutics Inc. (SNY) announces that Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics. The ongoing collaboration aims to advance in vivo genetic medicines using Scribe’s CRISPR by Design™ approach. Scribe will receive a milestone payment associated with the second target nomination and be eligible to receive additional development and commercial milestones upon advancement of the program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
News

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
none
-
News

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Rhea-AI Summary
Teva Pharmaceuticals (TEVA) closes collaboration deal with Sanofi (SAN, SNY) to co-develop and co-commercialize asset TEV '574, currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease. Teva to receive $500 million upfront payment and up to $1 billion in milestones. Joint development and profit sharing agreement with Sanofi. Estimated 10 million people worldwide live with IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News

Sanofi honors 10 advocacy organizations promoting health equity solutions in underserved U.S. communities

Rhea-AI Summary
Sanofi has announced the winners of its 2023 Health Equity Accelerator Awards, honoring 10 nonprofit organizations that exemplify the company's ambition to provide equitable access to healthcare using innovative solutions for hard-to-solve health disparities. Each winning organization will receive $50,000 from Sanofi and will be able to leverage the company's expertise through this partnership. In addition to the awards, Sanofi has launched a health equity Community of Practice to connect advocacy groups and share best practices. The company will also host a special event in January 2024 to celebrate the advocacy groups working to advance health equity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
News

Sanofi launches "The 1 Pledge" movement to drive early screening for type 1 diabetes in the U.S.

Rhea-AI Summary
Sanofi launches 'The 1 Pledge' movement to educate and encourage families to get screened for type 1 diabetes. The movement is supported by celebrities including Usher Raymond IV. Type 1 diabetes can be detected before symptoms arise and affects approximately 1.45 million Americans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
News

GoodRx Announces New Way for Consumers to Access Sanofi’s Lantus for $35 at Over 70,000 Pharmacies Nationwide

Rhea-AI Summary
GoodRx partners with Sanofi to offer affordable access to Lantus insulin for people with diabetes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
News

Sanofi Bridging the Gap between the Homeless and Society via Futsal

Rhea-AI Summary
Sanofi hosts founding ceremony of homeless futsal club 'Dream' as part of Helping Hands program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
none

FAQ

What is the current stock price of Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY)?

The current stock price of Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) is $47.71 as of December 20, 2024.

What is the market cap of Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY)?

The market cap of Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) is approximately 119.1B.

What does Sanofi specialize in?

Sanofi specializes in pharmaceuticals, focusing on oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments, and vaccines.

Where is Sanofi headquartered?

Sanofi is headquartered in Paris, France.

What is Dupixent?

Dupixent is a drug developed by Sanofi that accounts for over 20% of the company's sales, focusing on treating multiple conditions including asthma and dermatitis.

What recent acquisitions has Sanofi made?

Sanofi recently acquired Inhibrx's assets related to INBRX-101, a therapy for alpha-1 antitrypsin deficiency, valued at approximately $2.2 billion.

Who are Sanofi's primary markets?

Sanofi's primary markets include the United States (40% of revenue), Europe (25% of revenue), and various emerging markets.

What is the recent partnership between Sanofi and Novavax about?

Sanofi has partnered with Novavax to co-commercialize Novavax's adjuvanted COVID-19 vaccine globally, excluding some regions, and combine it with Sanofi's flu vaccines.

How does Sanofi approach sustainability?

Sanofi places a strong emphasis on sustainability and social responsibility, aiming to adopt eco-friendly practices and improve healthcare outcomes globally.

What percentage of Sanofi's revenue comes from the United States?

Approximately 40% of Sanofi's revenue comes from the United States.

What is the financial health of Sanofi?

Sanofi has a robust financial health, enabling it to invest in research and development and capitalize on new market opportunities.

What are Sanofi's future growth plans?

Sanofi plans to continue investing in research and development to drive innovation and future growth in the pharmaceutical sector.

Stock SNY logo
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)

NYSE:SNY

SNY Rankings

#104 Ranked by Market Cap
#729 Ranked by Dividends

SNY Stock Data

119.09B
2.51B
0%
11.43%
0.35%
Drug Manufacturers - General
Healthcare
Link
United States of America
Paris